Regulation of βAPP and PrPc cleavage by α-secretase: Mechanistic and therapeutic perspectives

Current Alzheimer Research

Volumn 5, Issue 2, 2008, Pages 202-211

  Vincent, Bruno ^a   Cisse, Moustapha Alfa ^a   Sunyach, Claire ^a   Guillot Sestier, Marie Victoire ^a   Checler, Frédéric ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA CASEIN; BETA SECRETASE; COLLAGEN TYPE 7; FIBRONECTIN; GAMMA SECRETASE; GELATIN; PRION PROTEIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; SECRETASE;

ALZHEIMER DISEASE; CREUTZFELDT JAKOB DISEASE; ENZYME REGULATION; HUMAN; NEUROPROTECTION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; HUMANS; PRION DISEASES; PRPC PROTEINS;

EID: 42149140619     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508783954749     Document Type: Review

References (110)

1. Alzheimer A. Uber eine eigenartige erkrankung der hirnrinde. Allg. Zeitschr. Psychiatr Psychiatr-Gerichtl Med 109: 146-148 (1907).
2. Glenner GG and Wong CW. Alzheimer's disease: initial report of purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890 (1984).
3. Goldgaber D, Lerman MI, McBride OW, Saffiotti U and Gajdusek DC. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 235: 877-880 (1987).
4. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736 (1987).
5. Robakis NK, Ramakrishna N, Wolfe G and Wiesniewski HM. Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptide. Proc Natl Acad Sci USA 854: 4190-4194 (1987).
6. Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St Georges-Hyslop P, Van Keuren ML, et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235: 880-884 (1987).
7. Citron M. β-secretase inhibition for the treatment of Alzheimer's disease-Promising challenge. Trends in Pharm Sci 25: 92-97 (2004).
8. Armogida M, Petit A, Vincent B, Scarzello S, Alves da Costa C and Checler F. Endogenous β-amyloid production in presenilin-deficient embryonic mouse fibroblasts. Nature Cell Biol 3: 1030-1033 (2001).
9. Wilson CA, Doms RW, Zheng H and Lee VMY. Presenilins are not required for Ab42 production in the early secretory pathway. Nature Neurosci 5: 849-855 (2002).
10. Lai MT, Crouthamel MC, DiMuzio J, Pietrak BL, Donoviel DB, Bernstein A, et al. A presenilin-independent aspartyl protease prefers the gamma-42 site cleavage. J Neurochem 96: 118-125 (2006).
11. Wolfe MS. The γ-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 45: 7931-7939 (2006).
12. Searfoss GH, Joran WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional γ-secretase inhibitor. J Biol Chem 278: 46107-46116 (2003).
13. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, et al. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279: 12876-12882 (2004).
14. Petit A, Bihel F, Alves da Costa C, Pourquié O, Checler F and Kraus JL. New protease inhibitors prevent γ-secretase-mediated production of Aβ40/42 without affecting notch cleavage. Nature Cell Biol 3: 507-511 (2001).
15. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414: 212-216 (2001).
16. Netzer WJ, Dou F, Cai D, Veach D, Jean S, Li Y, et al. Gleevec inhibits β-amyloid production but not Notch cleavage. Proc Natl Acad Sci USA 100: 12444-12449 (2003).
17. Palacino JJ, Berechid BE, Alexander P, Eckman C, Younkin S, Nye JS, et al. Regulation of amyloid precursor protein processing by presenilin 1 (PS1) and PS2 in PS1 knockout cells. J Biol Chem 275: 215-222 (2000).
18. Gandhi S, Refolo LM and Sambamurti K. Amyloid precursor protein compartmentalization restricts β-amyloid production: therapeutic targets based on BACE compartmentalization. J Mol Neurosci 24: 137-144 (2004).
19. Prusiner SB. Prions. Proc Natl Acad Sci USA 95: 13363-13383 (1998).
20. Chen SG, Teplow DB, Pachi P, Teller JK, Gambetti P and Autilio-Gambetti L. Truncated forms of the human prion protein in normal brain and in prion diseases. J Biol Chem 270: 19173-19180 (1995).
21. Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, Bugiani O, et al. Neurotoxicity of a prion protein fragment. Nature 362: 543-546 (1993).
22. Sisodia SS. β-amyloid precursor protein cleavage by a membranebound protease. Proc Natl Acad Sci USA 89: 6075-6079 (1992).
23. Kuentzel SL, Ali SM, Altman RA, Greenberg BD and Raub TJ. The Alzheimer β-amyloid protein precursor/protein nexin II is cleaved by secretase in a trans golgi secretory compartment in human neuroglioma cells. Biochem J 295: 367-378 (1993).
24. Shin RW, Saido TC, Maeda M and Kitamoto T. Novel α-secretase cleavage of Alzheimer's amyloid β precursor protein in the endoplasmic reticulum of COS7 cells. Neurosci Lett 376: 14-19 (2005).
25. Saitoh T, Sundsmo M, Roch JM, Kimura N, Cole G, Schubert D, et al. Secreted form of amyloid β protein precursor is involved in the growth regulation of fibroblasts. Cell 58: 615-622 (1989).
26. Pietrzik CU, Hoffmann J, Stöber K, Chen CY, Bauer C, Otero DA, et al. From differentiation to proliferation: the secretory amyloid precursor protein as a local mediator of growth in thyroid epithelial cells. Proc Natl Acad Sci USA 95: 1770-1775 (1998).
27. Quast T, Wehner S, Kirfel G, Jaeger K, De Luca M and Herzog V. sAPP as a regulator of dendritic motility and melanin release in epidermal melanocytes and melanoma cells. FASEB J 17: 1739-1741 (2003).
28. Caillé I, Allinquant B, Dupont E, Bouillot C, Langer A, Müller U, et al. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development 131: 2173-2181 (2004).
29. Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I and Rydel RE. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the β-amyloid precursor protein. Neuron 10: 243-254 (1993).
30. Furukawa K, Barger SW, Blalock EM and Mattson MP. Activation of K+ channels and suppression of neuronal activity by secreted β-amyloid precursor protein. Nature 379: 74-78 (1996).
31. Furukawa K and Mattson MP. Secreted amyloid precursor protein α selectively suppresses N-methyl-D-aspartate currents in hippocampal neurons: involvement of cyclic AMP. Neuroscience 83: 429-438 (1998).
32. Moechars D, Lorent K, De Strooper B, Dewachter I and Van Leuven F. Expression in brain of amyloid precursor protein mutated in the α-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J 15: 1265-1274 (1996).
33. Furukawa K, Sopher BL, Rydel RE, Begley JG, Pham DG, Martin GM, et al. Increased activity-regulating and neuroprotective efficacy of α-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J. Neurochem 67: 1882-1896 (1996).
34. Meziane H, Dodart JC, Mathis C, Little S, Clemens, Paul SM, et al. Memory-enhancing effects of secreted forms of the β-amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci USA 95: 12683-12688 (1998).
35. Hansel DE, Rahman A, Wehner S, Herzog V, Yeo CJ and Maitra A. Increased expression and processing of the Alzheimer amyloid precursor protein in pancreatic cancer may influence proliferation. Cancer Res 63: 7032-7037 (2003).
36. Alves da Costa C, Sunyach C, Pardossi-Piquard R, Sévalle J, Vincent B, Boyer N, et al. Presenilin-dependent g-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J Neurosci 26: 6377-6385 (2006).
37. Paitel E, Sunyach C, Alves da Costa C, Bourdon JC, Vincent B and Checler F. Primary cultured neurons devoid of cellular prion display lower responsiveness to staurosporine through the control of p53 at both transcriptional and post-transcriptional levels. J Biol Chem 279: 612-618 (2004).
38. Sunyach C, Alfa Cissé M, Alves da Costa C, Vincent B and Checler F. The C-terminal products of cellular prion protein processing, C1 and C2, exert distinct influence on p53-dependent staurosporine-induced caspase-3 activation. J Biol Chem 282: 1956-1963 (2007).
39. Büeler H, Fischer M, Lang Y, Bluethmann H, Lipp H, DeArmond S, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356: 577-582 (1992).
40. Büeler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, et al. Mice devoid of PrP are resistant to scrapie. Cell 73: 1339-1347 (1993).
41. Allinson TMJ, Parkin ET, Turner AJ and Hooper NM. ADAMs family members as amyloid precursor protein α-secretases. J. Neurosci Res 74: 342-352 (2003).
42. Seals DF and Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17: 7-30 (2003).
43. Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, et al. Evidence that tumor necrosis factor α-converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273: 27765-27767 (1998).
44. Vincent B, Paitel E, Saftig P, Frobert Y, Hartmann D, De Strooper B, et al. The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. J Biol Chem 276: 37743-37746 (2001).
45. Slack BE, Ma LK and Seah CC. Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-α converting enzyme. Biochem J 357: 787-794 (2001).
46. Alfa Cissé M, Gandreuil C, Hernandez JF, Martinez J, Checler F and Vincent B. Design and characterization of a novel cellular prion-derived quenched fluorimetric substrate of α-secretase. Biochem Biophys Res Commun 347: 254-260 (2006).
47. Alfa Cissé M, Sunyach C, Slack BE, Fisher A, Vincent B and Checler F. M1 and M3 muscarinic receptors control physiological processing of cellular prion by modulating ADAM17 phosphorylation and acticity. J Neurosci 27: 4083-4092 (2007).
48. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, et al. Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96: 3922-3927 (1999).
49. Lopez-Perez E, Zhang Y, Frank SLJ, Creemers J, Seidah N and Checler F. Constitutive α-secretase cleavage of the β-amyloid precursor protein in the furin-deficient LoVo cell line: involvement of the pro-hormone convertase 7 and the disintegrin ADAM10. J Neurochem 76: 1532-1539 (2001).
50. Hartmann D, De Strooper B, Serneels L, Craesserts K, Herreman A, Annaert W, et al. The disintegrin/metalloprotease ADAM10 is essential for notch signalling but not for α-secretase activity in fibroblasts. Hum Mol Genet 11: 2615-2624 (2002).
51. Alfa Cissé M, Sunyach C, Lefranc-Jullien S, Postina R, Vincent B and Checler F. The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity. J Biol Chem 280: 40624-40631 (2005).
52. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 113: 1456-1464 (2004).
53. Laffont-Proust I, Faucheux BA, Hässig R, Sazdovitch V, Simon S, Grassi J, et al. The N-terminal cleavage of cellular prion protein in the human brain. FEBS Lett 579: 6333-6337 (2005).
54. Koike H, Tomioka S, Sorimachi H, Saido TC, Maruyama K, Okuyama A, et al. Membrane-anchored metalloprotease MDC9 has an α-secretase activity responsible for processing the amyloid precursor protein. Biochem J 343: 371-375 (1999).
55. Hotoda N, Koike H, Sasagawa N and Ishiura S. A secreted form of human ADAM9 has an α-secretase activity for APP. Biochem Biophys Res Commun 293: 800-805 (2002).
56. Asai M, Hattori C, Szabo B, Sasagawa N, Maruyama K, Tanuma SI, et al. Putative function of ADAM9, ADAM10, and ADAM17 as APP α-secretase. Biochem Biophys Res Commun 301: 231-235 (2003).
57. Roghani M, Becherer JD, Moss ML, Atherton RE, Erdjument-Bromage H, Arribas J, et al. Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity. J Biol Chem 274: 3531-3540 (1999).
58. Tanabe C, Hotoda N, Sasagawa N, Sehara-Fujisawa A, Maruyama K and Ishiura S. ADAM19 is tightly associated with constitutive Alzheimer's disease APP α-secretase in A172 cells. Biochem Biophys Res Commun 352: 111-117 (2007).
59. Alkon DL, Sun MK and Nelson TJ. PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. Trends in Pharmacol Sci 28: 51-60 (2006).
60. Buxbaum JD, Gandy SE, Cicchetti P, Ehrlich ME, Czernik AJ, Fracasso RP, et al. Processing of Alzheimer β/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. Proc Natl Acad Sci USA 87: 6003-6006 (1990).
61. Vincent B, Paitel E, Frobert Y, Lehmann S, Grassi J and Checler F. Phorbol ester-regulated cleavage of normal prion protein in HEK293 human cells and murine neurons. J Biol Chem 275: 35612-35616 (2000).
62. Buxbaum JD, Koo EH and Greengard P. Protein phosphorylation inhibits production of Alzheimer amyloid β/A4 peptide. Proc Natl Acad Sci USA 90: 9195-9198 (1993).
63. Nitsch RM, Slack BE, Wurtman RJ and Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258: 304-307 (1992).
64. Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor. Proc Natl Acad Sci USA 89: 10075-10078 (1992).
65. Kojro E, Postina R, Buro C, Meiringer C, Gehrig-Burger K and Fahrenholz F. The neuropeptide PACAP promotes the α-secretase pathway for processing the Alzheimer amyloid precursor protein. FASEB J 20: 512-514 (2006).
66. Slack BE, Nitsch RM, Livneh E, Kunz GM, Breu J, Eldar H, et al. Regulation by phorbol esters of amyloid precursor protein release from Swiss 3T3 fibroblasts overexpressing protein kinase Cα. J Biol Chem 268: 21097-21101 (1993).
67. Kinouchi T, Sorimachi H, Maruyama K, Mizuno K, Ohno S, Ishiura S, et al. Conventional protein kinase C (PKC)-αand novel PKCε, but not δ, increase the secretion of an N-terminal fragment of Alzheimer's disease amyloid precursor protein from PKC cDNA transfected 3Y1 cells. FEBS Lett 364: 203-206 (1995).
68. Roßner S, Mendla K, Schliebs R and Bigl V. Protein kinase Cα and β1 are regulators of α-secretase secretory proteolytic processing of amyloid precursor protein in vivo. Eur J Neurosci 13: 1644-1648 (2001).
69. Xu H, Sweeney D, Greengard P and Gandy SE. Metabolism of Alzheimer β-amyloid precursor protein : regulation by protein kinase A in intact cells and in a cell-free system. Proc Natl Acad Sci USA 93: 4081-4084 (1996).
70. Marambaud P, Wilk S and Checler F. Protein kinase A phosphorylation of the proteasome: a contribution to the α-secretase pathway in human cells. J Neurochem 67: 2616-2619 (1996).
71. Efthimiopoulos S, Punj S, Manolopoulos V, Pangalos M, Wang GP, Refolo LM, et al. Intracellular cyclic AMP inhibits constitutive and phorbol ester-stimulated cleavage of amyloid precursor protein. J Neurochem 67: 872-875 (1996).
72. Marambaud P, Ancolio K, Alves da Costa C and Checler F. Effects of protein kinase A inhibitors on the production of Aβ40 and Aβ42 by human cells expressing normal and Alzheimer's disease-linked mutated βAPP and presenilin 1. Brit J Pharmacol 126: 1186-1190 (1999).
73. Suzuki T, Oishi M, Marshak DR, Czernik AJ, Nairn AC and Greengard P. Cell cycle-dependent regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor protein. EMBO J 13: 1114-1122 (1994).
74. Mills J, Charest DL, Lam F, Beyreuther K, Ida N, Pelech SL and Reiner PB. Regulation of amyloid precursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway. J Neurosci 17: 9415-9422 (1997).
75. Desdouits-Magnen J, Desdouits F, Takeda S., Syu LJ, Saltiel AR, Buxbaum JD, et al. Regulation of Alzheimer amyloid precursor protein by the mitogen-activated protein kinase cascade. J Neurochem 70: 524-530 (1998).
76. Petanceska SS and Gandy SE. The phosphatidylinositol 3-kinase inhibitor wortmannin alters the metabolism of the Alzheimer's amyloid precursor protein. J Neurochem 73: 2316-2320 (1999).
77. Roßner S, Ueberham U, Schliebs R, Perez-Polo JR and Bigl V. Regulated secretion of amyloid precursor protein by TrkA receptor stimulation in rat pheochromocytoma-12 cells is mitogen activated protein kinase sensitive. Neurosci Lett 271: 97-100 (1999).
78. Mudher A, Chapman S, Richardson J, Asuni A, Gibb G, Pollard C, et al. Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-jun terminal kinase. J Neurosci 21: 4987-4995 (2001).
79. Phiel CJ, Wilson CA, Lee VMY and Klein PS. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 423: 435-439 (2003).
80. Maillet M, Robert SJ, Cacquevel M, Gastineau M, Vivien D, Bertoglio J, et al. Crosstalk between Rap1 and Rac regulates secretion of sAPPα. Nature Cell Biol 5: 633-639 (2003).
81. Liu F, Su Y, Li B and Ni B. Regulation of amyloid precursor protein expression and secretion via activation of ERK1/2 by hepatocyte growth factor in HEK293 cells transfected with APP751. Exp Cell Res 287: 387-396 (2003).
82. Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME and Gandy S. Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. Plos Medicine 2: 69-78 (2005).
83. Bandyopadhyay S, Hartley DM, Cahill CM, Lahiri DK, Chattopadhyay N and Rogers JT. Interleukin-1α stimulates nonamyloidogenic pathway by α-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP kinase. J Neurosci Res 84: 106-118 (2006).
84. Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, et al. Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nature Med 4: 447-451 (1998).
85. Gouras GK, Xu H, Gross RS, Greenfield JP, Hai B, Wang R, et al. Testosterone reduces neuronal secretion of Alzheimer's β-amyloid peptides. Proc Natl Acad Sci USA 97: 1202-1205 (2000).
86. Emmerling MR, Moore CJ, Doyle PD, Carroll RT and Davis RE. Phospholipase A2 activation influences the processing and secretion of the amyloid precursor protein. Biochem Biophys Res Commun 197: 292-297 (1993).
87. Camden JM, Schrader AM, Camden RE, Gonzalez FA, Erb L, Seye CI, et al. P2Y2 nucleotide receptors enhance α-secretase-dependent amyloid precursor protein processing. J Biol Chem 280: 18696-18702 (2005).
88. Buxbaum JD, Ruefli AA, Parker CA, Cypess AM and Greengard P. Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc Natl Acad Sci USA 91: 4489-4493 (1994).
89. Borchardt T, Camakaris J, Cappai R, Masters CL, Beyreuther K and Multhaup G. Copper inhibits β-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. Biochem J 344: 461-467 (1999).
90. Schrader-Fischer G and Paganetti PA. Effescts of alkalizing agents on the processing of the β-amyloid precursor protein. Brain Res 716: 91-100 (1996).
91. Avramovich Y, Amit T and Youdim MBH. Non-steroidal antiinflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J Biol Chem 277: 31466-31473 (2002).
92. Colciaghi F, Borroni B, Zimmermann M, Bellone C, Longhi A, Padovani A, et al. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol Dis 16: 454-460 (2004).
93. Levites Y, Amit T, Mandel S and Youdim MB. Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3- gallate. FASEB J 17:952-954 (2003).
94. Zimmermann M, Borroni B, Cattabeni F, Padovani A and Di Luca M. Cholinesterase inhibitors influence APP metabolism in Alzheimer diseases patients. Neurobiol Dis 19: 237-242 (2005).
95. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49: 671-682 (2006).
96. Wang H, Lu Y and Wang Z. Function of cardiac M3 receptors. Autonomic Autocoid Pharmacol 27: 1-11 (2007).
97. Savage M, Trusko SP, Howland DS, Pinsker LR, Mistretta S, Reaume AG, et al. Turnover of amyloid protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci 18: 1743-1752 (1998).
98. Kozikowski AP, Nowak I, Petukhov PA, Etcheberrigaray R, Mohamed A, Tan M, et al. New amide-bearing benzolactam-based protein kinase C modulators induce enhanced secretion of the amyloid precursor protein metabolite sAPPα. J Med Chem 46: 364-373 (2003).
99. Etcheberrigaray R, Tan M, Dewachter I, Kuipéri C, Van der Auwera I, Wera S, et al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci USA 101: 11141-11146 (2004).
100. Kojro E, Gimpl G, Lammich S, März W and Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM10. Proc Natl Acad Sci USA 98: 5815-5820 (2001).
101. Obregon DF, Rezai-Zadeh K, Bai Y, Sun N, Hou H, Ehrhart J, et al. ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate- induced α-secretase cleavage of amyloid precursor protein. J Biol Chem 281: 16419-16427 (2006).
102. Marcello E, Gardoni F, Mauceri D, Romorini S, Jeromin A, Epis R, et al. Synapse-associated protein-97 mediates a-secretase ADAM10 trafficking and promotes its activity. J Neurosci 14: 1682-1691 (2007).
103. Endres K, Anders A, Kojro E, Gilbert S, Fahrenholz F and Postina R. Tumor necrosis factor-α converting enzyme is processed by proprotein- convertases to its mature form which is degraded upon phorbol ester stimulation. Eur J Biochem 270: 2386-2393 (2003).
104. Anders A, Gilbert S, Garten W, Postina R and Fahrenholz F. Regulation of the α-secretase ADAM10 by its prodomain and proprotein convertases. FASEB J 15: 1837-1839 (2001).
105. Galazka G, Windsor LJ, Birkedal-Hansen H and Engler JA. APMA (4-aminophenylmercuric acetate) activation of stromelysin-1 involves protein interactions in addition to those with cysteine-75 in the propeptide. Biochemistry 35: 11221-11227 (1996).
106. Fieber C, Baumann P, Vallon R, Termeer C, Simon JC, Hofmann M, et al. Hyaluronan-oligosaccharide-induced transcription of metalloproteases. J Cell Sci 117: 359-367 (2004).
107. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nature Med 5: 828-831 (1999).
108. Emi M, Katagiri T, Harada Y, Saito H, Inazawa J, Ito I, et al. A novel metalloprotease/disintegrin-like gene at 17q21.3 is somatically rearranged in two primary breast cancers. Nature Genet 5: 151-157 (1993).
109. Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW and Liu TY. Increase of disintegrin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma. Cancer Lett 245: 33-43 (2007).
110. Santiago-Josefat B, Esselens C, Bech-Serra JJ and Arribas J. Posttranscriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors. J Biol Chem 282: 8325-8331 (2007).